Literature DB >> 35083285

Epithelial-Specific TLR4 Knockout Challenges Current Evidence of TLR4 Homeostatic Control of Gut Permeability.

Elise E Crame1, Joanne M Bowen1, Kate R Secombe1, Janet K Coller2, Maxime François3,4, Wayne Leifert3,4, Hannah R Wardill1,5.   

Abstract

INTRODUCTION: Toll-like receptor 4 (TLR4) is a highly conserved immunosurveillance protein of innate immunity, displaying well-established roles in homeostasis and intestinal inflammation. Current evidence shows complex relationships between TLR4 activation, maintenance of health, and disease progression; however, it commonly overlooks the importance of site-specific TLR4 expression. This omission has the potential to influence translation of results as previous evidence shows the differing and distinct roles that TLR4 exhibits are dependent on its spatiotemporal expression.
METHODS: An intestinal epithelial TLR4 conditional knockout (KO) mouse line (Tlr4ΔIEC, n = 6-8) was utilized to dissect the contribution of epithelial TLR4 expression to intestinal homeostasis with comparisons to wild-type (WT) (n = 5-7) counterparts. Functions of the intestinal barrier in the ileum and colon were assessed with tissue resistance in Ussing chambers. Molecular and structural comparisons in the ileum and colon were assessed via histological staining, expression of tight junction proteins (occludin and zonular occludin 1 [ZO-1]), and presence of CD11b-positive immune cells.
RESULTS: There was no impact of the intestinal epithelial TLR4 KO, with no differences in (1) tissue resistance-ileum (mean ± standard error of mean [SEM]): WT 22 ± 7.2 versus Tlr4ΔIEC 20 ± 5.6 (Ω × cm2) p = 0.831, colon WT 30.8 ± 3.6 versus Tlr4ΔIEC 45.1 ± 9.5 p = 0.191; (2) histological staining (overall tissue structure); and (3) tight junction protein expression (% area stain, mean ± SEM)-ZO-1: ileum-WT 1.49 ± 0.155 versus Tlr4ΔIEC 1.17 ± 0.07, p = 0.09; colon-WT 1.36 ± 0.26 versus Tlr4ΔIEC 1.12 ± 0.18 p = 0.47; occludin: ileum-WT 1.07 ± 0.12 versus Tlr4ΔIEC 0.95 ± 0.13, p = 0.53; colon-WT 1.26 ± 0.26 versus Tlr4ΔIEC 1.02 ± 0.16 p = 0.45. CD11b-positive immune cells (% area stain, mean ± SEM) in the ileum were mildly decreased in WT mice: WT 0.14 ± 0.02 versus Tlr4ΔIEC 0.09 ± 0.01 p = 0.04. However, in the colon, there was no difference in CD11b-positive immune cells between strains: WT 0.53 ± 0.08 versus Tlr4ΔIEC 0.49 ± 0.08 p = 0.73.
CONCLUSIONS: These data have 2 important implications. First, these data refute the assumption that epithelial TLR4 exerts physiological control of intestinal physiology and immunity in health. Second, and most importantly, these data support the use of the Tlr4ΔIEC line in future models interrogating health and disease, confirming no confounding effects of genetic manipulation.
Copyright © 2021 by S. Karger AG, Basel.

Entities:  

Keywords:  Gastrointestinal homeostasis; Mucosal barrier function; Pre-clinical model; Toll-like receptor 4; Ussing chamber

Year:  2021        PMID: 35083285      PMCID: PMC8739639          DOI: 10.1159/000519200

Source DB:  PubMed          Journal:  Inflamm Intest Dis        ISSN: 2296-9365


  28 in total

1.  Toll-like receptor regulation of intestinal development and inflammation in the pathogenesis of necrotizing enterocolitis.

Authors:  Peng Lu; Chhinder P Sodhi; David J Hackam
Journal:  Pathophysiology       Date:  2013-12-22

Review 2.  Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function.

Authors:  Maria T Abreu
Journal:  Nat Rev Immunol       Date:  2010-02       Impact factor: 53.106

3.  Cis elements of the villin gene control expression in restricted domains of the vertical (crypt) and horizontal (duodenum, cecum) axes of the intestine.

Authors:  Blair B Madison; Laura Dunbar; Xiaotan T Qiao; Katherine Braunstein; Evan Braunstein; Deborah L Gumucio
Journal:  J Biol Chem       Date:  2002-06-13       Impact factor: 5.157

4.  Role of toll like receptors in irritable bowel syndrome: differential mucosal immune activation according to the disease subtype.

Authors:  Liliana Belmonte; Stéphanie Beutheu Youmba; Nathalie Bertiaux-Vandaële; Michel Antonietti; Stéphane Lecleire; Alberto Zalar; Guillaume Gourcerol; Anne-Marie Leroi; Pierre Déchelotte; Moïse Coëffier; Philippe Ducrotté
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

5.  The role of indoleamine 2,3-dioxygenase-aryl hydrocarbon receptor pathway in the TLR4-induced tolerogenic phenotype in human DCs.

Authors:  Fabián Salazar; Dennis Awuah; Ola H Negm; Farouk Shakib; Amir M Ghaemmaghami
Journal:  Sci Rep       Date:  2017-03-03       Impact factor: 4.379

6.  Immunogenicity Testing of Lipidoids In Vitro and In Silico: Modulating Lipidoid-Mediated TLR4 Activation by Nanoparticle Design.

Authors:  Anne Marit de Groot; Kaushik Thanki; Monique Gangloff; Emily Falkenberg; Xianghui Zeng; Djai C J van Bijnen; Willem van Eden; Henrik Franzyk; Hanne M Nielsen; Femke Broere; Nick J Gay; Camilla Foged; Alice J A M Sijts
Journal:  Mol Ther Nucleic Acids       Date:  2018-02-13       Impact factor: 8.886

7.  Toll-like receptor 4 (TLR4) deficiency aggravates dextran sulfate sodium (DSS)-induced intestinal injury by down-regulating IL6, CCL2 and CSF3.

Authors:  Yun-Jie Shi; Shi-Jie Hu; Quan-Quan Zhao; Xiao-Shuang Liu; Cong Liu; Hao Wang
Journal:  Ann Transl Med       Date:  2019-12

8.  Tolerance induced via TLR2 and TLR4 in human dendritic cells: role of IRAK-1.

Authors:  Valerie Albrecht; Thomas P J Hofer; Brian Foxwell; Marion Frankenberger; Loems Ziegler-Heitbrock
Journal:  BMC Immunol       Date:  2008-11-24       Impact factor: 3.615

Review 9.  TLR-Dependent Human Mucosal Epithelial Cell Responses to Microbial Pathogens.

Authors:  Ryan McClure; Paola Massari
Journal:  Front Immunol       Date:  2014-08-12       Impact factor: 7.561

Review 10.  TLR2 and TLR4 mediated host immune responses in major infectious diseases: a review.

Authors:  Suprabhat Mukherjee; Subhajit Karmakar; Santi Prasad Sinha Babu
Journal:  Braz J Infect Dis       Date:  2016-01-14       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.